Sami Hamade, Partner, Apple Tree Partners

With over 20 years of operating and investing experience across a broad spectrum of therapeutic areas, Sami is a prominent figure in the medical technology sector.  His interests include therapeutic devices, sensors and healthcare IT solutions.

Prior to joining Apple Tree Partners, Sami was a Partner at Aberdare Ventures where he oversaw the sale of Ablation Frontiers to Medtronic and participated in a number of key investments including NxThera Inc., Nevro and Sonitus.

In prior years, Sami was Vice President at the Guidant Corporation and head of the Compass Group, where he was responsible for Guidant’s venture capital, business development and M&A activities. Successful investments included Cardionet Inc (Nasdaq: BEAT), Evalve (Acquired by ABT), Cryovascular (Acquired by BSX), Remon medical (Acquired by BSX) Cardiomems (Acquired by St. Jude Medical) and Spiration Inc (Acquired by Olympus).

Earlier in his career, Sami played a critical operating role at Advanced Cardiovascular Systems (ACS), the pioneering company in the then emerging field of interventional cardiology which subsequently became a central part of Guidant’s multi-billion dollar leadership position in the stent market. He was also a senior executive in Guidant’s peripheral business. Sami has been a regular guest lecturer at the Stanford Business School and Biodesign programs. He is also an inventor and recipient of the prestigious Boss Kettering Award for innovation.

Sami holds a Bachelor’s Degree in Engineering from the American University of Beirut, a Masters Degree in Engineering from the University of Michigan, Ann Arbor and an MBA from the Stanford Graduate School of Business.

David McIntyre, Partner, Apple Tree Partners

David has over 20 years of experience as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles.

More recently, David was Executive Vice President, Chief Financial Officer of HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) from 2005 through 2011, and assumed the additional responsibilities of Chief Operating Officer during HeartWare’s global commercialization phase for the period from 2008 through 2011.

Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.

David holds a Bachelor of Economics (Accounting) from the University of Sydney (Australia), a Bachelor of Law from the University of Technology, Sydney (Australia) and a Masters of Business Administration (Fuqua Scholar) from Duke University. He is also a Certified Practicing Accountant (CPA) and is admitted as a Legal Practitioner of the Supreme Court of New South Wales (in Australia).

Amir Abolfathi, Apple Tree Partners Entrepreneur-in-Residence, and Tusker Medical CEO

Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices, dental products, hearing prosthetics, and genomic diagnostics & analytics. Amir was the inventor and founder of Sonitus Medical in 2006, a novel non-surgical hearing prosthetic designed for treatment of unilateral deafness, and Sonitus Technologies in 2010.  Prior to Sonitus, Amir held a variety of executive positions at Align Technology, Embolic Protection, and EndoTex as well as engineering roles at Pfizer, Guidant, and Baxter-Edwards.  Amir holds over 100 issued patents.

Amir received an MS in Engineering Management from the University of Southern California and a BS in Biomedical Engineering from the University of California, San Diego.